Latest News | PM Visit a Special Day for Company: Serum Institute of India
Get latest articles and stories on Latest News at LatestLY. Vaccine major Serum Institute of India on Saturday said it was a special day for the company with Prime Minister Narendra Modi visiting its facility in Pune to go into details on the manufacturing status of the coronavirus vaccine.
New Delhi, Nov 28 (PTI) Vaccine major Serum Institute of India on Saturday said it was a special day for the company with Prime Minister Narendra Modi visiting its facility in Pune to go into details on the manufacturing status of the coronavirus vaccine.
Modi visited Serum Institute of India on Saturday and interacted with the team at the Institute, an official release said. They shared details about their progress so far on how they plan to further ramp up vaccine manufacturing, it added.
Also Read | EPFO Extends Deadline to Submit Life Certificate by Pensioners Till February 28.
Addressing a virtual presser, Serum Institute of India CEO Adar Poonawalla said, "Worldwide everybody is now dependent and is looking forward to the vaccines coming out in large volumes and at affordable price from India as everybody already knows that more than 50 to 60 per cent of all vaccines are made in India."
"With the Aatmanirbhar Bharat vision in mind we have built the largest pandemic level facility in Pune in our sister campus at Manjri", and that was showcased also to the prime minister, he added.
Also Read | Petrol Price Crosses Rs 82 Mark in Delhi, Diesel Above Rs 72 a Litre.
About the discussion with the prime minister, he said: "We discussed the plan, the implementation plan which will happen only after the emergency use licence, that is granted based on the data that will have to be submitted. We are in the process of submitting that officially to the Drug Controller of India ...".
Serum Institute is conducting clinical trials of AstraZeneca-Oxford's COVID-19 vaccine candidate in India.
Earlier in a tweet, Adar Poonawalla said; "Sri @narendramodi Ji, it was a great honour for you to have spared the time, to visit us here at @SerumInstIndia to discuss in detail, the complex challenges yet to come and review the vaccine production status. @PMOIndia".
(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)